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Abstract 
Background: Allergic rhinitis (AR) is characterised by burdensome nasal and/or ocular symptoms. This inflammatory 
disease can be debilitating and thus result in considerable health-related and economic consequences.
Methods: In a cross-sectional study, adult subjects with AR (N = 683) completed three allergy-specific question-
naires that assessed the impact of AR on the work/academic performance, daily activities, health-related quality of life 
(HRQOL), and satisfaction with allergen immunotherapy (AIT). Regression analyses were used to examine the associa-
tions between several clinical variables and the patient-reported outcomes.
Results: Total loss of productivity was 21.0 and 21.2 % for employed and student patients, respectively, whereas the 
impairment of daily activities was 22.0 %. The mean overall HRQOL score was 1.94 ± 1.29 (on the scale of 0–6 points). 
Global score for satisfaction with AIT was 65.5 ± 24.8 (on a 0–100 scale). Simple regression analysis found statistically 
significant associations between loss of work and academic productivity, impairment of daily activities and the type 
and severity of AR. AIT was a protective factor. The persistent and more severe types of AR and lack of AIT contributed 
to the worsening of HRQOL.
Conclusions: AR (the persistent and more severe form of the disease) has an impact on functional characteristics of 
adult patients in Spain. AIT might reduce the effect of this disease on the work/academic performance and HRQOL.
Trial registration Retrospectively registered
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Background
Allergic rhinitis (AR) affects more than 400 million peo-
ple worldwide, with high prevalence recorded in the 
developed countries [1, 2]. It is characterized primarily 
by nasal symptoms such as sneezing, itching, rhinorrhea, 
nasal congestion, and post-nasal drip. Loss of taste and 
smell, allodynia, or mouth breathing and snoring due to 
nasal congestion may also occur. The bothersome nature 
of AR symptoms can severely affect daily activities such 
as the ability to work [3–5], examination performance 
[6], quality of life [7], and psychosocial well-being [8].
AR is also associated with substantial economic costs 
[9, 10]. Indirect costs of work and school absenteeism 
due to AR have been estimated to be higher than those 
caused by diabetes, migraine, anxiety, or asthma [11]. 
Moreover, when the patients attend their workplaces, the 
symptoms lead to reduced productivity, a major problem 
known as “presenteeism” [12]. The studies of the socioec-
onomic burden of productivity loss have shown that AR 
and depression are of some of the most frequent causes 
of absenteeism, particularly during spring season [13]. 
The understanding of the social impact is important; a 
relationship between treatment adherence, health-related 
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quality of life (HRQOL), and performance has been 
already demonstrated in pathologies such as asthma [14].
In Spain, a previous study estimated direct and indirect 
costs of AR, showing the important economic burden of 
the disease [15]. The work of de la Hoz Caballer et al. [5] 
compared the effect of AR on HRQOL and work perfor-
mance with the impact of other prevalent diseases such 
as hypertension, diabetes mellitus type II, and sympto-
matic depression. In the present study, we conducted an 
extensive examination of the impact of AR on functional 
characteristics of the patients (work/academic productiv-
ity and daily activities) and HRQOL, and assessed their 
satisfaction with the treatment. Several factors (patient- 
and disease-related characteristics, the type of treat-
ment) potentially associated with impaired performance, 
HRQOL, or satisfaction with the treatment, were also 
evaluated.
Methods
The study was a cross-sectional, observational study con-
ducted in allergy departments in Spain from May 2011 
to October 2012. The study was approved by the Insti-
tutional Ethics Committee of the Hospital German Trias 
i Pujol (Badalona, Spain) and was conducted in accord-
ance with the principles of the Declaration of Helsinki. 
Before participation, all patients had signed the informed 
consent form.
A number of physicians from different regions were 
selected to cover the geographical area of Spain (Fig. 1). 
Each physician included 6–7 consecutive patients 
throughout the four seasons of the year, preferably in a 
uniform manner (i.e. 2-2-1-1; 1-2-2-1; 1-1-2-2; 2-1-1-2). 
Patients were over 18 years old, experiencing AR (accord-
ing to ARIA and Valero criteria [1, 16]), diagnosed by a 
prick test or specific IgE, and poorly controlled (may be 
also with symptomatic treatment). The patients had a 
stable job or pursued an academic activity. Any comor-
bidity that could affect work/study performance accord-
ing to the physician’s criteria was an exclusion criterion. 
Patients participating in other clinical study or unable 
to understand or complete the questionnaires were also 
excluded.
The study data collection was performed during a sin-
gle visit. Physicians completed a patient record form for 
each patient. The record included demographic charac-
teristics, the information on the years since diagnosis of 
the disease, allergens/factors inducing nasal symptoms, 
disease severity, number of visits to the specialist in the 
last 12  months, symptoms and comorbidities (asthma, 
conjunctivitis, atopic dermatitis, etc.), symptomatic 
treatment for AR, and the use of allergen immunotherapy 
(AIT).
Patient‑reported health outcomes
Patients were invited to complete several self-report ques-
tionnaires. To evaluate the burden of illness, the Work 
Productivity and Activity Impairment Questionnaire 
and Classroom Impairment Questions: Allergy Specific 
(WPAI  +  CIQ:AS) were used [17]. The WPAI-CIQ-AS 
is a 9-item, patient-reported questionnaire. The patients 
reported the work time or academic classes lost due to the 
allergies. They self-assessed the impact of allergies on the 
performance in the workplace, at school, or during uni-
versity classes. The patients also described the effect of 
allergies on other daily activities; they were asked to recall 
such activities during the previous 7 days. Outcomes were 
expressed as impairment percentages, with higher scores 
indicating greater impairment and reduced productivity.
The HRQOL assessment was performed using the 
ESPRINT-15 tool, the short form of the Spanish ques-
tionnaire specifically designed for AR patients [18, 19]. 
This questionnaire contains 15 items within the following 
dimensions: symptoms (5 items), daily activities (3 items), 
sleep (3 items), psychological impact (3 items), and gen-
eral health (1 item). The overall score and the score for 
each dimension were registered, on a scale from 0 (no 
impact on HRQOL) to 6 (maximum impact on HRQOL).
The Satisfaction Scale for Patients Receiving Allergen 
Immunotherapy (ESPIA; from Spanish, “Escala de Satis-
facción de Pacientes en tratatamiento con Inmunoterapia 
con Alérgenos”) questionnaire [20] was used to deter-
mine the satisfaction of patients receiving AIT treat-
ment. The questionnaire consists of 16 items distributed 
among four dimensions: perceived efficacy, activities and 
Fig. 1 Distribution of the recruiting regions involved in the study to 
cover the geographical area of Spain. The map shows autonomus 
communities from Spain. Blue colour means ≤5 recruiting investiga-
tors involved; green 5–10 investigators; orange 10–15 investigators; 
and red ≥15 investigators
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environment, cost–benefit balance, and general satisfac-
tion. The questionnaire scores (overall and for the four 
dimensions) are obtained by transforming the sum of its 
items to a 0–100-point scale, with low scores indicating 
low levels of satisfaction.
Statistical analysis
We performed data management and statistical analysis 
using the SPSS software package (version 14; SPSS Inc. 
Chicago, IL, USA). A descriptive analysis was conducted, 
describing categorical variables using numbers and per-
centages, and quantitative variables using means and 
standard deviation (SD).
For the association of quantitative variables, the 
Kruskal–Wallis and Mann–Whitney tests were used. We 
determined predictive factors for impaired productiv-
ity and quality of life by using linear regression analysis. 
The dependent variables were the scores in the patient 
questionnaires. The multivariable model was developed, 
based on a backwards selection from the variables with 
significance in bivariate analysis. All statistical tests were 
considered significant at P < 0.05.
Results
Patient demography and clinical description
The study enrolled 683 patients recruited by 144 physi-
cians. The patient demographics are shown in Table  1. 
Overall, 332 (48.6  %) were men and the mean age was 
33.2  ±  10.3  years. The majority of patients (n  =  525, 
78.8  %) were employed or self-employed; 137 (21.1  %) 
were full-time students and 4 (0.6 %) were studying and 
working.
Clinical information is presented in Table  2. Mean 
time since rhinitis diagnosis was 10.8  ±  8.8  years. In 
most cases, the diagnosis of allergy was conducted using 
skin-prick tests (98.8  %) and/or serum allergen-specific 
IgE (62.8  %). The most common etiological allergens 
were pollens only in 48.1 %, followed by dust mites only 
in 29.1 % and both allergens pollen and mites in 20.5 %. 
The frequency of intermittent and persistent AR was 
29.4 and 70.6 %, respectively. According to ARIA criteria, 
92 (13.5  %) patients had mild AR and 591 (86.5  %) had 
moderate/severe AR, whereas Valero’s criteria classified 
92 (13.5  %) as mild, 380 (55.6  %) as moderate, and 211 
(30.9 %) as severe. In the preceding 12 months, the mean 
number of control visits to the allergist was 3.0 ± 2.6. The 
majority of patients (486, 71.2 %) were undergoing phar-
macological treatment for AR symptoms. On the con-
sultation day, 403 (59.0  %) and 61 (8.9  %) patients were 
Table 1 Sociodemographic characteristics of patients
N = 683
Sex (males), N (%) 332 (48.6)
Age (years), mean ± SD 33.2 ± 10.3
Educational level, N (%)
 Basic literacy 9 (1.3)
 Primary level 73 (10.7)
 Secondary level 289 (42.3)
 Completed university 300 (43.9)
Employment status, N (%)
 Employed and/or self-employed 525 (78.8)
 Full-time student 137 (20.6)
 Student and employee 4 (0.6)
Table 2 Clinical and disease information
AIT allergen immunotherapy, AR allergy rhinitis, SCIT subcutaneous 
immunotherapy, SD standard deviation, SLIT sublingual immunotherapy
N = 683
AR duration (years), mean ± SD 10.8 ± 8.8
Etiologic allergen, N (%)
 Dust mite 199 (30.0)
 Pollen 325 (48.9)
 Dust mite and pollen 140 (21.1)
Type of AR, N (%)
 Intermittent 200 (29.4)
 Persistent 480 (70.6)
ARIA Severity of AR, N (%)
 Mild 92 (13.5)
 Moderate/severe 591 (86.5)
VALERO severity of AR, N (%)
 Mild 92 (13.5)
 Moderate 380 (55.6)
 Severe 211 (30.9)
Current pharmacological treatment, N (%)
 No 197 (28.8)
 Yes 486 (71.2)
Current allergen immunotherapy, N (%)
 No 159 (23.8)
 Yes 508 (76.2)
  SCIT 304 (60.7)
  SLIT 194 (38.7)
  Both 3 (0.6)
Time from current AIT initiation (months), mean ± SD 12.8 ± 14.2
Current use of medication versus before AIT initiation, N (%)
 More medication 10 (1.9)
 The same medication 112 (20.7)
 Less medication 418 (77.4)
Current level of symptoms versus before AIT initiation, N (%)
 More symptoms 10 (1.9)
 The same level of symptoms 92 (17.1)
 Less symptoms 437 (81.1)
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receiving oral and/or topical antihistamines, respectively; 
269 patients (39.4  %) were receiving nasal corticoster-
oids. Thirteen patients (1.9 %) were undergoing oral cor-
ticosteroid treatment and 47 patients (6.9 %) were being 
treated with antileukotrienes. From the large proportion 
of patients under AIT (508, 76.2  %), 304 (60.7  %) were 
given subcutaneous immunotherapy (SCIT) and 194 
(38.3  %) were given sublingual immunotherapy (SLIT). 
Most of these patients stated that after the initiation 
of AIT they had used less medication (77.4  %) and had 
fewer symptoms (81.1 %).
Patient‑reported measures
Mean WPAI  +  CIQ:AS scores were similar for the 
employed and the students, with the loss of productiv-
ity of 21.0 and 21.2  %, respectively. Overall mean value 
for the impairment of daily life activities was 22.0  %. 
The mean overall HRQOL score assessed using the 
ESPRINT-15 tool was 1.94 ± 1.29 (scale of 0–5.8 points). 
The symptom dimension had a high score (2.21 ± 1.38), 
whereas daily activities were less affected (1.67 ±  1.47). 
The global score in the ESPIA questionnaire filled by 
the patients under AIT (n  =  508) was 65.5  ±  24.8 (on 
a 0–100 scale). Overall satisfaction with the treatment 
had the highest score (73.4 ±  25.7), while the score for 
the activity and environment dimension was the lowest 
(61.8 ± 27.3).
Factors associated with impaired productivity, HRQOL, 
and satisfaction with AIT
Initially in the bivariate analysis, several clinical parame-
ters were identified as potential factors significantly asso-
ciated with impaired work/academic productivity and 
daily activities (Table 3): age, sex, education level, dura-
tion of AR, number of visits, type of AR, AR severity, and 
concurrent AIT. 
Simple regression analysis confirmed that work pro-
ductivity was associated with the education level, with 
more education associated with less disease impact, type 
and severity of AR (persistent and more severe AR asso-
ciated with more impairment), and current AIT (less 
impact with AIT). Academic productivity was associated 
with age (older people had lower impaiment), type of 
AR (persistent AR affected more), and current AIT (less 
impact with AIT). Impact on daily activities was associ-
ated with sex (female patients more affected), type and 
severity of AR (persistent and severe forms had a greater 
impact), and current AIT (less with AIT).
 As shown in Table  4, persistent and more severe AR 
and absence of current AIT all contributed to worse 
HRQOL in both employed and student patients.
For the ESPIA scores, employed patients with persis-
tent and more severe AR were less satisfied with their 
AIT, while being allergic to both dust mite and pollen and 
suffering intermittent AR were associated with higher 
scores in student patients. There was no significant dif-
ference between satisfaction with SCIT and sublingual 
immunotherapy (SLIT) (Table 5).
Discussion
For the first time in Spain and under “real life” condi-
tions, the ENERGY study examined the impact of AR 
on work/academic performance and HRQOL of adult 
patients poorly controlled with or without pharmaco-
logical treatment. The study used the validated question-
naires WPAI  +  CIQ-AS, ESPRINT-15, and ESPIA, the 
tools specifically developed for allergies. Our results sug-
gest that AR affects several functional areas. The data are 
in accord with the existing reports of the impairment of 
work/academic productivity [3, 4, 6] and HRQOL [7, 8] 
by AR in other countries. As could be expected, the nega-
tive impact of AR was more pronounced in patients with 
persistent and more severe forms of the disease, aspect 
already observed in a previous study conducted in Spain 
[15, 21]. The patients in these groups were less satisfied 
with their AIT than other patients.
The WPAI questionnaire has been used before to quan-
tify the impact of several pathologies, such as irritable 
bowel disease, Crohn’s disease, and ankylosing spondy-
litis, on various aspects of productivity [22–24]. Here, 
absenteeism from workplace or classroom caused by AR 
(assessed by the WPAI  +  CIQ:AS) was relatively low. 
The work/class impairment (presenteeism) and overall 
loss of work/academic productivity were around 21  %. 
The affected patients might not perform well in their 
work or studies, their job- and class-related relationships 
might be damaged, and their professional growth might 
suffer. The participants also reported negative effects of 
AR outside work or study class; these effects are referred 
to as daily activity impairment. WPAI + CIQ:AS scores 
in this study were slightly lower than those published in 
previous reports. De la Hoz Caballer et  al. [5] found an 
overall loss of work productivity of 26.8 %. However, they 
have used the generic WPAI questionnaire to compare 
the impact of different pathologies attended to in pri-
mary care centers. A Japanese study used WPAI-AS to 
evaluate the effect of oral fexofenadine on work produc-
tivity of seasonally allergic patients [25]. They reported 
an overall loss of productivity of 38.0  %. However, they 
did not include the mild AR patients and the study was 
conducted during pollen season [25]. AR symptoms are 
often experienced by the patients at work or at the aca-
demic center; thus, presenteeism is highly relevant to the 
evaluation of costs associated with AR [8]. Indeed, AR 
shares common pathophysiological components with 
asthma, otitis media, chronic sinusitis, upper respiratory 
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infections, and nasal polyps [26, 27]. When these comor-
bidities are viewed as part of the continuum of AR dis-
ease, the overall cost of AR increases considerably [28, 
29]. A population survey in Northern California has 
assessed the relative work loss and decrease in productiv-
ity during 4 weeks of AR and asthma in 400 adults. The 
results showed similar work loss levels for the two condi-
tions, 23 % for AR and 24 % for asthma. However, among 
the symptomatic individuals who stayed at work, 36 % of 
patients with AR were less effective at their jobs in com-
parison with 19 % of asthma sufferers [3].
Impairment in HRQOL of AR patients has been a 
frequent object of study [8, 30]. Disease-specific ques-
tionnaires, such as the ESPRINT-15 tool, are the instru-
ments most widely accepted for HRQOL evaluation. 
The ESPRINT-15 questionnaire accurately describes the 
problems most commonly associated with the disease. It 
includes the sleep loss caused by the AR symptoms, lead-
ing to fatigue and lack of concentration during the day, 
psychological effects, and deterioration in daily activities 
[8]. The present study showed that the increase in the 
persistence and severity of AR symptoms augmented the 
effect on patient HRQOL, similarly to previous results 
[21, 31]. The patients undergoing AIT reported bet-
ter HRQOL than the individuals not receiving AIT. This 
finding confirms the reports that the severity of the AR 
has a stronger effect on the quality of life of patients than 
the duration of the disease [32].
These results justify the effort put into optimizing the 
allergy therapies. Pharmacological treatments are gener-
ally effective and well tolerated, improve sleep quality, 
reduce daytime fatigue [33, 34], and improve work pro-
ductivity [35] and quality of life [30, 36]. However, the 
patients receiving such treatment often present poor lev-
els of control of their nasal symptoms. Specific AIT can 
induce specific immune tolerance and has a long-term dis-
ease-modifying effect. Nevertheless, it is associated with 
low adherence [37], possibly because of a large number of 
administrations and the duration of the therapeutic course. 
The ESPIA questionnaire explores the pivotal aspects of 
subjective experience with AIT, such as self-perceived effi-
cacy, daily life activities, cost–benefit balance, and general 
satisfaction. Importantly, the cost–benefit balance section 
assesses the compatibility of the daily “inconveniences,” 
Table 4 Factors potentially associated with  impairment in  health-related quality of  life (ESPRINT-15) according to  the 
bivariate and simple regression models
“Excluded” are the factors discarded by the regression model as potentially associated with productivity impairment
A mean overall score of the ESPRINT-15 questionnaire on the scale of 0 (no impact on HRQOL) to 6 (maximum impact on HRQOL)
 Significance values are in italics
AIT allergen immunotherapy, AR allergic rhinitis, SD standard deviation
* P-value for the bivariate analysis was calculated using Mann–Whitney or Kruskal–Wallis tests for independent samples, with a confidence interval of 95 %
Factors Health‑related quality of life (ESPRINT‑15)
Adults working Adults studying
n Bivariate analysis Simple regression n Bivariate analysis Simple regression
Mean score SD P value* Beta coefficient Mean score SD P value* Beta coefficient
Sex
 Male 259 1.79 1.22 0.002 0.276 57 1.81 1.2 0.564
 Female 257 2.18 1.38 77 1.94 1.15
Number of visits to allergist
 <3 293 2.07 1.34 0.069 82 2.03 1.26 0.081 −0.048
 ≥3 218 1.87 1.28 51 1.62 0.98
Type of AR
 Intermittent 140 1.37 1.06 0.000 0.333 46 1.42 1.04 0.001 0.461
 Persistent 376 2.21 1.33 86 2.14 1.17
 Mild 70 1.04 0.87 16 0.93 0.85
VALERO severity
 Moderate 282 1.86 1.14 0.000 8.359 80 1.84 1.05 0.000 0.438
 Severe 164 2.59 1.46 38 2.37 1.27
Current AIT
 No 122 2.73 1.23 0.000 −0.813 29 2.87 1.13 0.000 −1.113
 Yes 382 1.74 1.25 103 1.6 1.03
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Table 5 Factors potentially associated with satisfaction with AIT (ESPIA) according to the bivariate and simple regression 
models
“Excluded” are the factors discarded by the regression model as potentially associated with productivity impairment
Mean overall scores of the ESPIA questionnaire are obtained from the sum of its items with transformation to a 0–100-point scale
 Significance values are in italics
AIT allergen immunotherapy, AR allergic rhinitis, SD standard deviation
* P-value for the bivariate analysis was calculated using Mann–Whitney or Kruskal–Wallis tests for independent samples, with a confidence interval of 95 %
#  In the population of adult students, all variables were included in the simple regression due to lack of significance in the initial bivariate analysis
Factors Satisfaction with AIT (ESPIA)
Adults working Adults studying
n Bivariate analysis Simple Regression n Bivariate analysis Simple regression#
Mean score SD P value* Beta coefficient Mean score SD P value* Beta coefficient
Age (years)
 <35 180 63.01 25.64 0.040 Excluded 96 65.43 24.3 0.495 Excluded
 ≥35 206 68.08 24.44 6 62.19 17.38
Sex
 Male 200 66.18 26.49 0.347 45 62.12 25.89 0.35 8.491
 Female 186 65.21 23.58 57 67.71 22.11
Educational level
 Basic literacy 6 69.79 25.52 0.924 2 42.19 26.52 0.167 Excluded
 Primary level 51 64.65 24.38 5 44.06 37.41
 Secondary level 139 65.19 25.85 56 64.52 22.08
 Completed university
Duration of AR (years)
 <9 194 67.88 24.09 0.095 62 67.42 22.68 0.374 Excluded
 ≥9 190 63.67 25.57 39 61.89 25.91
Etiologic allergen
 Dust mite 111 62.49 25.32 0.118 37 62.4 26.8 0.976 6.757
 Pollen 190 66.68 25.27 41 63.9 21.27
 Both 75 67.51 25 21 75.72 18.44
Familiar history of atopy
 Yes 214 64.81 26.59 0.689 68 66.11 23.72 0.766 Excluded
 No 166 67.17 23.06 33 64.77 23.73
Number of visits to allergist
 <3 196 66.07 24.76 0.888 57 65.44 22.73 0.898 Excluded
 ≥3 187 65.22 25.49 45 64.98 25.54
Type of AR
 Intermittent 118 74.19 20.92 0.000 −9.232 36 71.01 19.02 0.123 −10.012
 Persistent 268 61.98 25.9 65 62.5 25.75
VALERO severity
 Mild 66 78.6 20.61 0.000 −4.308 14 75.68 23.63 0.079 Excluded
 Moderate 205 63.84 24.7 64 65.65 22.17
 Severe 115 61.66 25.98 24 58.05 26.91
His tory of allergy
 No 48 66.71 21.47 0.85 13 56.88 27.74 0.223 Excluded
 Yes 338 65.57 25.6 89 66.46 23.2
Type AIT
 SCIT 231 66.73 26.36 0.184 54 63.28 26.72 0.845 Excluded
 SLIT 141 65.19 22.79 41 67.03 19.43
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caused by the logistics of the treatment administration, 
with the lifestyle of the patient. It makes possible to estab-
lish whether these inconveniences are compensated by 
AIT efficacy, which is a crucial determinant of adherence. 
Here, the overall satisfaction with AIT was high, espe-
cially for patients with intermittent and mild forms of AR, 
and independently of receiving SLIT or SCIT. According 
to their reports, most of the patients receiving AIT had 
reduced the use of pharmacological agents and were expe-
riencing fewer symptoms since the initiation of the therapy. 
The regression analyses revealed that AIT was associated 
with decreased impact on work/academic productivity, on 
daily activities, and overall HRQOL. The ESPIA question-
naire and other patient-reported scales, along with exist-
ing efficacy assessment tools (symptom scores, current 
medication), may help to balance efficacy with tolerability 
in regular clinical practice. There are some limitations to 
the study to be considered. The inherent limitations in all 
observational and cross-sectional studies did not allow the 
assessment of the long-term effects. Despite that patients 
were included during May and October and most of them 
were allergic to pollens and/or HDM, meaning that they 
must be at their peak symptomatic seasons, we could not 
establish whether the results would hold true during the 
periods of high or low allergen counts. The patient selec-
tion comprised the whole range of AR severity, including 
mild and intermittent disease, which might have reduced 
the perceived impact on patient activity performance and 
HRQOL. The studied individuals were under different 
treatment regimens and their combinations. Some treat-
ments might have caused somnolence, affecting the work/
academic productivity and precluding the attribution of 
the observed impairment solely to AR symptoms. Indeed, 
in this study, sleep quality was only evaluated as an item of 
the ESPRINT-15 questionnaire. Furthermore, all the sub-
jects in our study were under the care of an allergist and 
were continuing on SCIT or SLIT that they found benefi-
cial. Therefore, it is not possible to make comparisons with 
patients who have failed or refused immunotherapy. Nev-
ertheless, our results suggest a social impact on the overall 
AR population and should lead to larger, prospective stud-
ies with populations that are more specific. To reduce the 
socioeconomic impact of AR symptoms, we urgently need 
to determine the real burden of this common disease and 
find the most effective medical interventions.
Conclusion
Our results showed a negative impact of AR on work/
academic productivity and HRQOL of patients receiving 
pharmacological treatment in several allergy departments 
in Spain. Several factors such as persistent AR or a more 
severe form of the disease were associated with higher 
impairment of the studied functional outcomes. Specific 
AIT may play a protective role, improving productiv-
ity and HRQOL of AR patients. A more comprehensive 
interaction between patient and physician might be 
required to reduce the current socioeconomic burden of 
this disease. Various parameters including nature, sever-
ity, and impact of AR symptoms on self-perceived health-
related measures should be taken into account.
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